OPKO Health announced that the FDA has approved Rayaldee (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT)...
OPKO Health, Inc. presented late-breaking clinical data on Rayaldee extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia
OPKO Health has announced successful top-line results from the second and final pivotal Phase III trial of Rayaldee as a...
OPKO Health, Inc.has announced that it has submitted a New Drug Application (NDA) for oral Rayaldee (vitamin D prohormone) to...
OPKO Health, Inc. announced that the FDA has issued a complete response letter (CRL) to the Company's New Drug Application...
Amgen announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with...